Balcom Alexandra, serving as Chief Financial Officer, has demonstrated a pronounced selling bias in recent insider transactions, as evidenced by SEC Form 4 filings. Over the course of 56 trades, Alexandra has sold shares totaling $17,022,479.40, while purchasing shares worth $2,929,360.08. This significant disparity underscores a clear preference for divestment over accumulation. Notably, all 21 of the most recent transactions, spanning from November 2025 to March 2026, were sales, with no buys recorded during this period. The transactions were exclusively tied to Nuvation Bio, Inc. (NUVL), indicating a concentrated focus on this single stock.
The recent sales were substantial in both frequency and value. For instance, on March 25, 2026, Alexandra sold shares valued at $1,372,192, followed by multiple transactions on March 24, 2026, totaling over $1,094,419.45. Earlier in January 2026, a series of sales occurred, including transactions on January 5 and 6, with values ranging from $31,230.84 to $159,134.55. These transactions, along with others in late 2025, such as a $770,405.04 sale on December 8, 2025, and multiple sales exceeding $300,000 in November 2025, highlight a consistent pattern of significant divestment. The absence of any recent buys and the high volume of sales suggest a strategic shift in Alexandra’s holdings, particularly in NUVL. This activity provides a clear snapshot of insider behavior, emphasizing a sustained trend of reducing exposure to this specific equity.
AI-assisted summary